Safety follow-up survey for MELAS taurine high-dose therapy subjects after completion of doctor-initiated clinical trial

Safety follow-up survey for MELAS taurine high-dose therapy subjects after completion of doctor-initiated clinical trial - Safety follow-up survey for MELAS taurine high-dose therapy subjects

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029376

Enrollment

Registered

2017-10-16

Start date

2017-10-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MELAS

Interventions

High-dose taurine supplementation

9-12 g/day,, three times after meal, every day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects continuing the taurine bulk mass method in doctor-initiated clinical trials beginning in 2013, up to 8 subjects

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Safety assessment: (i) adverse event report, (ii) annual blood test	—

Countries

Japan

Contacts

Public ContactYoshihide Sunada

Kawasaki medical School Neurology

ysunada@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026